Innovative research suggests that rapamycin, a drug traditionally used to prevent organ transplant rejection, could potentially extend women’s fertility by up to five years. This revelation comes from a pilot study involving women aged 35-45, which indicated that rapamycin might decrease ovarian ageing by 20%, thereby possibly adding five fertile years. The drug works by reducing the number of follicles recruited per menstrual cycle, preserving the ovarian reserve longer. Although the study’s initial cohort was small, the promising results have paved the way for a larger trial with 1,000 women. This research not only opens new avenues for fertility treatment but also exemplifies the broader potential of repurposing existing drugs for new therapeutic applications, including women’s health issues like ovarian cancer and improving uterine conditions for embryo implantation.
Read more at ScienceAlert…
